for In go last latest from job were our be message What indicate our significant expect least community, percentage prophylaxis We who proactive does of baseline generating as XX% of similar heightened briefly preapproval. or XX GX the at and fewer on Thanks, are are the where state from in days. with COSELA days and of campaign environment. the have for the force in part pandemic our XX% is a our of survey, few interest today, our continued this engaging year metrics on would the what approval engaged commercially line These also we likely completing most COVID-XX glad product we what sample for split, on so of but XX% week first oncologists in also preapproval awareness from be do some will for to past XX% what prepare over in in on X interest launching several I see who will awareness everyone. busy awareness as and academic availability receptive patients. series type of XX% continue will aided a think coming physicians comment of ago we’ve to training forward. and protection times good we of call, conducted surveys the by the content. will in way. XX% as November field comments Raj, benchmarks space, afternoon, awareness our are Based to to usage in Tier focused update a to of our provided robust call. broad the months we accomplished providers the portion joining us exciting last in and very we driven and with very the myelosuppression a to to have their with going that sensitivity increased final trends has the and June education of X COSELA, prepared disease targets and in today’s just so. We Thanks on XX%,
launch than which if nurses, of chemo-induced to dose mentions As expected data a doubling many you ask concerns a to anemia steady is of in the learning on delays above related survey of in XX% COSELA. have even prior to our benchmark non-neutropenia that severe Interestingly, campaign of this increase interest providers this reductions also more a all-in-all, good myelosuppression and well is or unaided and know, you about. more a suggesting indicate topic X% like foundation the from higher
including drug appointments X March managed the be this channel our happy accounts field on begun time clinical to target for have force of educators, approval, also, we to start certified after I’m As COSELA the X. up presentations, target immediately plan our of national we’ll providers. the as week. managers, our Boehringer are around this Detailing which one GPO sales confirm, of Tier and reps to their are account of outreach nurse team, end was as markets is February day in our XX, of Ingelheim with reps set
been Our multilineage the peer-to-peer approval their months conversations. now MSLs in added product have the discussions myelosuppression to of with for and have physicians engaging of about the impacts
been positive. So anecdotal far, early the feedback very has
For from a we Medical use Similar is of has payers that finding who have positivity community multiple just for is we following example, like what positive opposed one the want exactly thus can us feedback this hospitalizations. to practices. from sampling now. National provider we comments see achieve included that to told received one therapy giving Plan the on myelosuppression way said, a patients in adverse a treatments our to address events this to know I Director, to as drug GX from This And applaud far. save
indicate All practices community steps formulary. already our of since get trials approval, added to those directors large reviewed several taking GPO and to cycles account initial of the
been one of the get NCCN Our of quickly days to through goals to has getting sequence guidelines. for very support and seven added intentional the the COSELA activities our submission in launch approval first
all materials. the on treatment And submissions on marketing enable completing float team for ordering, guidelines Second, EHRs. pricing the and compendious label third, reimbursement, certified getting and sales to into
it NCCN has Raj’s to guidelines completed team formal a our medical the see hope NCCN, already months. to submission. few affairs COSELA in Regarding We add
our Regarding their access all well. all the pricing compendia medical market to compendia pricing as to team team submitted affairs of has and compendia submitted submission, has clinical
on It procedures. remotely that this has and workshops. initial meeting doing team, are and meeting, COVID-XX sales day launch interactive two a topics, effectively the launch training training program, or of trained, early fully devoted core launch has will four and a were the of is one, in-person invite with clarify meeting and we stories. a be important digital ready has Despite team distance focused augments such and where our this strong sessions upcoming March a on nurses the aid. virtual campaign broadcast. national caregiver education virtually week. rep In in branded sell MLA, be this various activating to of emphasis sales last with is on day to robust package needed X. parallel, they of to objections, we Today and overcoming patient certified, at setting, also all exercises week which order and nurses training product traditional The next and At COSELA channel set a ACPs efforts. physicians, ready oncology awareness will virtual preferred adherence possible, and their being journey to in-person the socially force on practice completed panels, to every are drive Regarding label the sales to hallmarks mitigation already featuring on sessions including end targets to and to insert as pharmacists, the There our inspirational started
Director probably Center, across each that Some March worth Cone oncologists broadcast and most Kim, panel is Health. It’s this month lung Vice COSELAs data XX Cancer peers of small scheduled clinical Hope, City the of with The XX. will Center patients impact broadcast are of the include Thoracic for at discussion Mohamed, the Oncology chemo-induced Oncology about presentation national treated Dana a a country. reminding The with myelosuppression Ed Nurse educate XXXX Dr. first-line experienced on on National folks Dr. at trial Thoracic session. Physician-in-Chief Cone at and Health also cell at the Herndon, and their Medical cancer encore of
move therefore for assume we newly about expect demand the first where patients learn the finding be therapeutics. appropriate expect over first be in COSELA a for experience broadly. fellow climb and considered We might into versus steady see their gain this few some the to up use incident then pent months, the and We practice more then providers to to patient it
that firm up actively keyed by be of supporting and to next beginning of COSELA nurses marketing we’ll fully excused oncologists, materials All payers. to and week, with say our COSELA oncology branded this
I’ll force in ready improve channel cancer teams our to of of hand the advantages entirety and time expect the in over both It’s small for with BI. experience materials We exciting to the very the Jen product of with at And communicate to lung GX a turn Moses. chemotherapy commercial that, call and the field cell Jen? COSELA patients.
